Core Laboratories N.V.
NYSE:CLBOil & Gas Equipment & Services
+$0.12 today
- Market cap
- $387.21M
- Beta
- 0.99
- P/E (TTM)
- 18.3
- EPS (TTM)
- $0.63
- Dividend yield
- 0.35%
Volume 0.52M
Average 0.49M
CLB Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Core Laboratories N.V.NYSE: CLB
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q1 FY2026 depreciation & amortization of $3.76M rose 1.3% year over year, behind the +24.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 2.6% from the prior quarter. Over 3 fiscal years it compounded at -5.1% a year.
Context
- Depreciation & amortization amounted to 2.8% of revenue in FY2025, unchanged from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +1.3% toward the trailing-twelve-month pace of +24.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 14.65M USD
- Year-over-year change
- -2.0%
- 4-year CAGR
- -5.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.65M | -2.0% |
| FY2024 | 2024-12-31 | 14.95M | -5.3% |
| FY2023 | 2023-12-31 | 15.78M | -8.0% |
| FY2022 | 2022-12-31 | 17.16M | -7.3% |
| FY2021 | 2021-12-31 | 18.52M | — |
Depreciation & Amortization vs competitors
How CLB compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +24.2% is the 3rd highest of 10, against a peer median of +14.3%.
- Depreciation & amortization amounts to 3.5% of revenue for CLB, versus a peer median of 28.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $650.78M USD | +3.2% | -0.8% | 20.1% | |
| LTM Mar 2026 | $426.05M USD | -11.1% | +33.4% | 55.3% | |
| LTM Mar 2026 | CA$327.2M CAD | +6.9% | +5.8% | 17.5% | |
| LTM Mar 2026 | $222.24M USD | +20.8% | +26.8% | 48.8% | |
| LTM Mar 2026 | $154.6M USD | +14.3% | +8.3% | 14.7% | |
| LTM Mar 2026 | $134.04M USD | +29.7% | +26.6% | 48.7% | |
| LTM Mar 2026 | $100.17M USD | +43.0% | +32.7% | 28.2% | |
| LTM Mar 2026 | $93.75M USD | +12.2% | +3.6% | 2.6% | |
| LTM Mar 2026 | $18.41M USD | +24.2% | -5.1% | 3.5% | |
| LTM Mar 2026 | $13.77M USD | +16.9% | — | 1083.6% | |
| Peer median (excluding CLB) | — | +14.3% | +17.5% | 28.2% | |
Competitors are the stored peer set for CLB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 470.25M | 489.74M | 509.79M | 523.85M | 526.52M |
| Cost of Revenue | 386.41M | 410.82M | 415.74M | 435.48M | 432.24M |
| Gross Profit | 83.84M | 78.92M | 94.05M | 88.37M | 94.28M |
| Gross Margin | 17.8% | 16.1% | 18.4% | 16.9% | 17.9% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 44.17M | 38.12M | 38.89M | 38.59M | 44.23M |
| Operating Expenses | 38.58M | 37.4M | 39.41M | 29.82M | 43.8M |
| Depreciation & Amortization | 18.52M | 17.16M | 15.78M | 14.95M | 14.65M |
| EBITDA | 63.78M | 58.69M | 70.42M | 73.51M | 71.12M |
| EBITDA Margin | 13.6% | 12.0% | 13.8% | 14.0% | 13.5% |
| Operating Income | 45.26M | 41.52M | 54.64M | 58.56M | 50.49M |
| Operating Margin | 9.6% | 8.5% | 10.7% | 11.2% | 9.6% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 9.15M | 11.57M | 13.43M | 12.37M | 10.57M |
| Other Income / Expenses | (9.15M) | (11.57M) | (13.43M) | (12.37M) | (4.59M) |
| Income Before Tax | 36.11M | 29.95M | 41.21M | 46.19M | 45.9M |
| Pre-Tax Margin | 7.7% | 6.1% | 8.1% | 8.8% | 8.7% |
| Income Tax Expense | 15.89M | 10.3M | 4.19M | 14.03M | 15.51M |
| Net Income | 19.73M | 19.45M | 36.68M | 31.4M | 29.67M |
| Net Margin | 4.2% | 4.0% | 7.2% | 6.0% | 5.6% |
| EPS (Basic) | 0.43 | 0.42 | 0.79 | 0.67 | 0.68 |
| EPS (Diluted) | 0.42 | 0.42 | 0.77 | 0.66 | 0.68 |
| Weighted Avg Shares | 46.01M | 46.33M | 46.68M | 46.9M | 46.5M |
| Weighted Avg Shares (Diluted) | 46.69M | 46.81M | 47.52M | 47.69M | 46.5M |
Core Laboratories N.V.
NYSE:CLB
Intrinsic Alpha fair value
Locked
Current Price
$8.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.